← Funding Tracker

Oli (formerly Baymatob) Raises A$6.5M Series A3

Australian intrapartum monitoring wearable startup. Led by Scale Investors, Clare Ventures, and University of Sydney. Funds pivotal clinical trials across seven sites in Australia and the US, plus TGA and FDA regulatory submissions.

The Deal

Oli, an Australian medtech startup formerly known as Baymatob, raised A$6.5M (about US$4.2M) in a Series A3 round backed by Scale Investors, Clare Ventures, and the University of Sydney. The company builds a wireless wearable that simultaneously monitors maternal and fetal signals during labor across roughly 10 biosensors, translating raw inputs into live clinical signals that flag patterns preceding postpartum hemorrhage, fetal distress, and stillbirth risk. The round brings total private capital to about A$13M alongside more than A$9.5M in non-dilutive grants, and funds pivotal clinical trials across seven sites in Australia and the US, plus TGA and FDA regulatory submissions ahead of commercial launch.

Context

This is the only verifiable new maternal-pediatric venture round to surface in the week-of-June-9 scan, and one of the few intrapartum (during-labor) predictive monitoring plays in a field otherwise crowded with antepartum remote monitoring and NICU bedside devices. Intrapartum monitoring is a real white space: the incumbent standard (cardiotocography) is decades old and a known source of both missed deterioration and unnecessary intervention, so a multi-signal wearable with a predictive layer is a structurally interesting bet if the clinical trials and FDA path hold. The caveat is that Oli is Australia-first with US entry still gated on pivotal trial readouts and FDA clearance, so US reimbursement and adoption are years out. Note the date: the round was announced May 27, 2026, just outside the strict 7-day scan window, but it had not previously been filed in the vault and was not caught by the June 3 scan, so it is logged here as net-new.